Jane Rocha Duarte Cintra

Jane Rocha Duarte Cintra

Auto-generated profile, based on publicly available information

Jane Rocha Duarte Cintra

Instituto Oncológico Hospital Nove de Julho, Brasil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
ACAngélica Atala Lombelo Campos
Angélica Atala Lombelo Campos
MBMaria Teresa Bustamante-Teixeira
Maria Teresa Bustamante-Teixeira
RERafaela Russi Ervilha
Rafaela Russi Ervilha
VFVivian Assis Fayer
Vivian Assis Fayer
JCJane Rocha Duarte Cintra
Jane Rocha Duarte Cintra
MGMaximiliano Guerra
Maximiliano Guerra
Highlights Sociodemographic, clinical, and lifestyle factors impact the quality of life of breast cancer survivors. Breast cancer therapy may affect future perspectives and emotional, cognitive, and sexual function. Some aspects of quality of life still require attention from health professionals. ABSTRACT Objective: Patients with cancer often undergo multiple extended treatments that decrease their quality of life. However, the quality of life of women with breast cancer after they undergo treatment remains underexplored in Brazil. Therefore, this study determined sociodemographic, behavioral,

1 January 2022 in Revista Gaucha de Enfermagem
Verified
Journal Article
Open access
ACAngélica Atala Lombelo Campos
Angélica Atala Lombelo Campos
MGMaximiliano Guerra
Maximiliano Guerra
VFVívian Assis Fayer
Vívian Assis Fayer
RERafaela Russi Ervilha
Rafaela Russi Ervilha
JCJane Rocha Duarte Cintra
Jane Rocha Duarte Cintra
MBMaria Teresa Bustamante-Teixeira
Maria Teresa Bustamante-Teixeira
Objective: To analyze the time to diagnosis and treatment for breast cancer and the associated factors, according to the type of care (public vs. private). Methodology: Retrospective cohort study with 477 women diagnosed with breast cancer between 2014 and 2016. Data were collected in an oncology service in a municipality in Minas Gerais, in the 2018-2019 period. Analyzes were performed using the Kaplan-Meier method and Cox's proportional regression model. Results: The median time to diagnosis was 70 days, being shorter for women who discovered the disease through screening tests and who were diagnosed in early stages of the disease. The median time for treatment was 32 days, which was shorter for women assisted by private health service, with a high level of education and who were diagnosed in early stages. Conclusions: Private care and facilitators of access to breast cancer care were associated with shorter waiting times.

1 March 2024 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
DRDaniela O. Werneck Rodrigues
Daniela O. Werneck Rodrigues
RDRoberta Wolp Diniz
Roberta Wolp Diniz
LDLeonardo Cunha Dentz
Leonardo Cunha Dentz
MCMonica de Albuquerque Costa
Monica de Albuquerque Costa
RLRoberto Heleno Lopes
Roberto Heleno Lopes
CDChristian Domenge
Christian Domenge
Rosai-Dorfman Disease (RDD) is a rare non-Langerhans histiocytosis, usually self-limited and presenting with massive, painless, bilateral cervical lymphadenopathy, with or without constitutional symptoms. Extranodal disease is frequently present, and may happen in the absence of lymph node involvement, symptomatology and differential diagnosis will depend on the site affected and fatal cases may occur. The authors present two cases of Rosai-Dorfman disease (RDD), diagnosed through immunohistochemistry, with different progressions, one with complete remission and one culminating in death, highlighting the variety of presentations and the diagnostic difficulty. RDD is a rare condition with clinical presentations similar to several diseases, and should be considered in the differential diagnosis of lymphadenopathy with extranodal lesions.

1 January 2022 in Revista Gaucha de Enfermagem
Verified
Journal Article
Open access
ACAngélica Atala Lombelo Campos
Angélica Atala Lombelo Campos
MGMaximiliano Guerra
Maximiliano Guerra
VFVívian Assis Fayer
Vívian Assis Fayer
RERafaela Russi Ervilha
Rafaela Russi Ervilha
JCJane Rocha Duarte Cintra
Jane Rocha Duarte Cintra
MBMaria Teresa Bustamante-Teixeira
Maria Teresa Bustamante-Teixeira
RESUMO Objetivo: Analisar o tempo para o diagnóstico e tratamento do câncer de mama e os fatores associados, segundo o tipo de assistência (pública vs. privada). Métodos: Coorte retrospectiva com 477 mulheres diagnosticadas com câncer de mama entre 2014-2016. Os dados foram coletados em um serviço de oncologia de um município de Minas Gerais, entre 2018-2019. As análises foram realizadas pelo método de Kaplan-Meier e pelo modelo de regressão de Cox. Resultados: O tempo mediano para diagnóstico foi de 70 dias, sendo menor para aquelas que descobriram a doença por exames de rastreamento e diagnosticadas em estádios iniciais. O tempo mediano para o tratamento foi de 32 dias, sendo menor para as mulheres assistidas pela rede privada, com alta escolaridade e diagnosticadas em estádios iniciais. Conclusões: Assistência na rede privada e facilitadores do acesso ao cuidado do câncer de mama associaram-se a menores tempos de espera.

25 April 2022 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
RFRenata Mendes de Freitas
Renata Mendes de Freitas
MGMaximiliano Guerra
Maximiliano Guerra
VFVívian Assis Fayer
Vívian Assis Fayer
ACAngélica Atala Lombelo Campos
Angélica Atala Lombelo Campos
JCJane Rocha Duarte Cintra
Jane Rocha Duarte Cintra
MBMaria Teresa Bustamante-Teixeira
Maria Teresa Bustamante-Teixeira
Objective The study aimed to characterize the clinical, histological, and immunohistochemical profile of women with invasive breast cancer, according to the risk for Hereditary Predisposition Breast and Ovarian Cancer Syndrome in a Brazilian population. Methods This is a retrospective study performed from a hospital-based cohort of 522 women, diagnosed with breast cancer treated at an oncology referral center in the Southeast region of Brazil, between 2014 and 2016. Results Among the 430 women diagnosed with invasive breast cancer who composed the study population, 127 (29.5%) were classified as at increased risk for hereditary predisposition to breast and ovarian cancer syndrome. There was a lower level of education in patients at increased risk (34.6%) when compared with those at usual risk (46.0%). Regarding tumor characteristics, women at increased risk had higher percentages of the disease diagnosed at an advanced stage (32.3%), and with tumors > 2cm (63.0%), with increased prevalence for both characteristics, when compared with those at usual risk. Furthermore, we found higher percentages of HG3 (43.3%) and Ki-67 ≥ 25% (64.6%) in women at increased risk, with prevalence being about twice as high in this group. The presence of triple-negative tumors was observed as 25.2% in women at increased risk and 6.0% in women at usual risk, with the prevalence of absence of biomarkers being 2.5 times higher among women in the increased risk group. Conclusion From the clinical criteria routinely used in the diagnosis of breast cancer, the care practice of genetic counseling for patients at increased risk of hereditary breast cancer in contexts such as Brazil is still scarce. Objetivo O presente estudo buscou caracterizar o perfil clínico, histológico e imunohistoquímico de mulheres com câncer de mama invasivo segundo o risco para a Síndrome de Predisposição Hereditária ao Câncer de Mama e Ovário em uma população brasileira. Métodos Trata-se de um estudo retrospectivo realizado a partir de uma coorte hospitalar composta por 522 mulheres diagnosticadas com câncer de mama entre 2014 e 2016 assistidas em um centro de referência oncológica localizado na região sudeste brasileira. Resultados Entre as 430 mulheres diagnosticadas com câncer de mama invasivo que compuseram a população de estudo, 127 (29,5%) foram classificadas como de risco aumentado para a síndrome de predisposição hereditária ao câncer de mama e ovário. Verificou-se menor nível de escolaridade nas pacientes com risco aumentado (34,6%) quando comparadas àquelas consideradas como de risco habitual (46,0%). Quanto às características do tumor, as mulheres de risco aumentado apresentaram maiores percentuais de doença diagnosticada em estádio avançado (32,3%) e com tumores > 2cm (63,0%), com prevalência aumentada para ambas as características, quando comparadas àquelas de risco habitual. Ainda nas mulheres de risco aumentado, foram encontrados maiores percentuais de GH3 (43,3%) e Ki-67 ≥ 25% (64,6%), com prevalência cerca de duas vezes maior neste grupo. A presença de tumores triplo-negativos foi observada em 25,2% nas mulheres de risco aumentado e 6,0% nas mulheres de risco habitual, com prevalência de ausência de biomarcadores 2,5 vezes maior entre as mulheres do grupo de risco aumentado. Conclusão A partir dos critérios clínicos rotineiramente utilizados no diagnóstico do câncer de mama, a prática assistencial do aconselhamento genético para as pacientes com risco aumentado de câncer de mama hereditário em contextos como o do Brasil ainda é escarça. Freitas analyzed the data, and promoted the conception and design of the article. Guerra helped in the analysis and writing of the article. Fayer and Campos participated in data collection. Cintra contributed to the screening of patients in the cohort and the collection of clinical information. Warren contributed substantially to the interpretation of the data and performed a critical review of its intellectual content. Ervilha participated in the data collection and writing of the article. De Paula acted in the graphic presentation of the results, and Teixeira performed a relevant critical review of the intellectual content presented with approval of the final version to be published. Received: 29 October 2021 Accepted: 01 December 2021 Publication Date: 25 April 2022 (online) © 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

1 January 2022 in Mastology
Verified
Journal Article
Open access
RFRenata Mendes de Freitas
Renata Mendes de Freitas
GAGilda Alves
Gilda Alves
MGMaximiliano Guerra
Maximiliano Guerra
ACAngélica Atala Lombelo Campos
Angélica Atala Lombelo Campos
LDLucas Delmonico
Lucas Delmonico
MBMaria Teresa Bustamante-Teixeira
Maria Teresa Bustamante-Teixeira
Introduction: Malignant breast cancer is the second most common type of cancer among women in the world, leaving behind nonmelanoma skin cancer. The aim of this study was to identify germline variants in the BRCA1 and BRCA2 genes in women diagnosed with breast cancer in the southeastern region of Brazil. Methods: This study is part of a retrospective study, performed from a hospital-based cohort, consisting of 522 women. 92 patients were excluded from the study because they had carcinoma in situ and did not present clinical information, totaling 430 patients. Of these, we performed molecular investigation in 46 patients. BRCA2 variants were detected in 10/46 (22%) women. From 7 missense variants identified, 5 and 2 showed benign and uncertain significance, respectively. Two synonymous variants not previously reported were considered of uncertain significance (c.2622T>A; c.2721G>A), and one nonsense variant showed pathogenic clinical significance (c.2847T>A). Results: The results showed that gene sequencing in individuals with a high risk of hereditary cancer is necessary, as it may reveal new variants, or initially described with uncertain significance. Conclusion: Although this study was conducted with a small cohort of selected breast cancer patients, it reinforces the importance of investigating the Brazilian population due to the finding of the pathogenic variant and genetic counseling.